Vitamin K Epoxide Reductase Complex Subunit 1
VKORC1 is warfarin's molecular target. A common promoter variant determines how much VKORC1 your liver produces, and therefore how much warfarin it takes to block the vitamin K cycle enough to thin your blood.
Gene2Rx covers 1 medication with published pharmacogenetic guidance for VKORC1, drawn from CPIC and FDA sources. Each drug links to its full pharmacogenetics page.
These branded medications include at least one active ingredient whose metabolism or action involves VKORC1. Each links to its full pharmacogenetic breakdown.
This page lists drugs affected by VKORC1. A Gene2Rx report tells you which metabolizer group you fall into, and what that means for every medication on this list.
Get your report Look up a medicationInformational only, not medical advice. The presence of a VKORC1 pharmacogenetic guideline does not mean every patient needs to change their dose. Never start, stop, or change a medication without talking to your prescribing clinician.